** Shares of drug developer Viking Therapeutics VKTX.O fall 8% to $30.82 premarket
** Co reported quarterly earnings in Wednesday, in which it also said its late-stage trial for the subcutaneous or under-the-skin version of experimental obesity drug VK2735 will start in Q2
** Investors were hoping for some meaningful developments, but the updates were mostly incremental, which sent shares lower - brokerage J.P.Morgan
** J.P.Morgan and another brokerage Oppenheimer say update was largely inline with expectations, although some investors were anticipating an earlier trial initiation
** Shares more than doubled in 2024
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.